These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32115956)

  • 1. Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.
    Liang J; Huang YY; Zhou Q; Gao Y; Li Z; Wu D; Yu S; Guo L; Chen Z; Huang L; Liang SH; He X; Wu R; Luo HB
    J Med Chem; 2020 Mar; 63(6):3370-3380. PubMed ID: 32115956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel PDE4 inhibitors targeting the M-pocket from natural mangostanin with improved safety for the treatment of Inflammatory Bowel Diseases.
    Liu H; Wang Q; Huang Y; Deng J; Xie X; Zhu J; Yuan Y; He YM; Huang YY; Luo HB; He X
    Eur J Med Chem; 2022 Nov; 242():114631. PubMed ID: 35985255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mangostanin Derivatives as Novel and Orally Active Phosphodiesterase 4 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis with Improved Safety.
    Huang YY; Deng J; Tian YJ; Liang J; Xie X; Huang Y; Zhu J; Zhu Z; Zhou Q; He X; Luo HB
    J Med Chem; 2021 Sep; 64(18):13736-13751. PubMed ID: 34520193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of rolipram and roflumilast, phosphodiesterase-4 inhibitors, on hypertension-induced defects in memory function in rats.
    Jabaris SG; Sumathy H; Kumar RS; Narayanan S; Thanikachalam S; Babu CS
    Eur J Pharmacol; 2015 Jan; 746():138-47. PubMed ID: 25446433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.
    Davis TG; Peterson JJ; Kou JP; Capper-Spudich EA; Ball D; Nials AT; Wiseman J; Solanke YE; Lucas FS; Williamson RA; Ferrari L; Wren P; Knowles RG; Barnette MS; Podolin PL
    J Pharmacol Exp Ther; 2009 Sep; 330(3):922-31. PubMed ID: 19498103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PAN-selective inhibition of cAMP-phosphodiesterase 4 (PDE4) induces gastroparesis in mice.
    McDonough W; Aragon IV; Rich J; Murphy JM; Abou Saleh L; Boyd A; Koloteva A; Richter W
    FASEB J; 2020 Sep; 34(9):12533-12548. PubMed ID: 32738081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of triazines as potent, selective and orally active PDE4 inhibitors.
    Gewald R; Grunwald C; Egerland U
    Bioorg Med Chem Lett; 2013 Aug; 23(15):4308-14. PubMed ID: 23806553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of N-Alkyl Catecholamides as Selective Phosphodiesterase-4 Inhibitors with Anti-neuroinflammation Potential Exhibiting Antidepressant-like Effects at Non-emetic Doses.
    Zhou ZZ; Cheng YF; Zou ZQ; Ge BC; Yu H; Huang C; Wang HT; Yang XM; Xu JP
    ACS Chem Neurosci; 2017 Jan; 8(1):135-146. PubMed ID: 27690383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational design of conformationally constrained oxazolidinone-fused 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
    Song G; Zhu X; Li J; Hu D; Zhao D; Liao Y; Lin J; Zhang LH; Cui ZN
    Bioorg Med Chem; 2017 Oct; 25(20):5709-5717. PubMed ID: 28888661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
    Wollin L; Bundschuh DS; Wohlsen A; Marx D; Beume R
    Pulm Pharmacol Ther; 2006; 19(5):343-52. PubMed ID: 16257550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring phosphodiesterase-4 inhibitors using liquid chromatography/(tandem) mass spectrometry in sports drug testing.
    Thevis M; Krug O; Schänzer W
    Rapid Commun Mass Spectrom; 2013 May; 27(9):993-1004. PubMed ID: 23592202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Nonhuman Primate PET Study: Measurement of Brain PDE4 Occupancy by Roflumilast Using (R)-[
    Takano A; Uz T; Garcia-Segovia J; Tsai M; Lahu G; Amini N; Nakao R; Jia Z; Halldin C
    Mol Imaging Biol; 2018 Aug; 20(4):615-622. PubMed ID: 29441434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses.
    Vanmierlo T; Creemers P; Akkerman S; van Duinen M; Sambeth A; De Vry J; Uz T; Blokland A; Prickaerts J
    Behav Brain Res; 2016 Apr; 303():26-33. PubMed ID: 26794595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Roflumilast analogs as soft PDE4 inhibitors.
    Boland S; Alen J; Bourin A; Castermans K; Boumans N; Panitti L; Vanormelingen J; Leysen D; Defert O
    Bioorg Med Chem Lett; 2014 Sep; 24(18):4594-4597. PubMed ID: 25149511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the therapeutic index of a novel phosphodiesterase 4B-selective inhibitor over phosphodiesterase 4D in mice.
    Suzuki O; Mizukami K; Etori M; Sogawa Y; Takagi N; Tsuchida H; Morimoto K; Goto T; Yoshino T; Mikkaichi T; Hirahara K; Nakamura S; Maeda H
    J Pharmacol Sci; 2013; 123(3):219-26. PubMed ID: 24152964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of oral and inhaled PDE4 inhibitors.
    Ting PC; Lee JF; Kuang R; Cao J; Gu D; Huang Y; Liu Z; Aslanian RG; Feng KI; Prelusky D; Lamca J; House A; Phillips JE; Wang P; Wu P; Lundell D; Chapman RW; Celly CS
    Bioorg Med Chem Lett; 2013 Oct; 23(20):5528-32. PubMed ID: 24018187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The phosphodiesterase-4 inhibitor roflumilast decreases ethanol consumption in C57BL/6J mice.
    Liu X; Hao PD; Yang MF; Sun JY; Mao LL; Fan CD; Zhang ZY; Li DW; Yang XY; Sun BL; Zhang HT
    Psychopharmacology (Berl); 2017 Aug; 234(16):2409-2419. PubMed ID: 28477089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species.
    Rutter AR; Poffe A; Cavallini P; Davis TG; Schneck J; Negri M; Vicentini E; Montanari D; Arban R; Gray FA; Davies CH; Wren PB
    J Pharmacol Exp Ther; 2014 Jul; 350(1):153-63. PubMed ID: 24784567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation.
    Konrad FM; Bury A; Schick MA; Ngamsri KC; Reutershan J
    PLoS One; 2015; 10(4):e0121725. PubMed ID: 25909327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and bioactivity of phenyl substituted furan and oxazole carboxylic acid derivatives as potential PDE4 inhibitors.
    Lin Y; Ahmed W; He M; Xiang X; Tang R; Cui ZN
    Eur J Med Chem; 2020 Dec; 207():112795. PubMed ID: 33002845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.